VYNE Therapeutics Inc. (NASDAQ:VYNE – Get Rating)’s stock price fell 6.4% on Monday . The company traded as low as $0.26 and last traded at $0.26. 107,271 shares were traded during mid-day trading, a decline of 82% from the average session volume of 606,849 shares. The stock had previously closed at $0.28.
Wall Street Analyst Weigh In
VYNE has been the subject of a number of recent research reports. Lifesci Capital downgraded shares of VYNE Therapeutics from an “outperform” rating to a “market perform” rating in a report on Friday, August 12th. HC Wainwright reduced their target price on shares of VYNE Therapeutics from $7.00 to $1.50 and set a “buy” rating for the company in a report on Wednesday, August 10th.
VYNE Therapeutics Stock Down 6.4 %
The stock has a 50-day moving average of $0.26 and a 200 day moving average of $0.36. The stock has a market cap of $15.10 million, a PE ratio of -0.37 and a beta of 1.25.
Institutional Investors Weigh In On VYNE Therapeutics
Hedge funds have recently bought and sold shares of the stock. Mackenzie Financial Corp purchased a new stake in VYNE Therapeutics in the 1st quarter worth approximately $42,000. Beacon Pointe Advisors LLC purchased a new position in shares of VYNE Therapeutics during the 1st quarter valued at approximately $49,000. Cetera Advisor Networks LLC purchased a new position in shares of VYNE Therapeutics during the 2nd quarter valued at approximately $45,000. Bailard Inc. purchased a new position in shares of VYNE Therapeutics during the 1st quarter valued at approximately $91,000. Finally, Renaissance Technologies LLC lifted its position in shares of VYNE Therapeutics by 6.7% during the 1st quarter. Renaissance Technologies LLC now owns 965,098 shares of the company’s stock valued at $627,000 after buying an additional 60,567 shares in the last quarter. Hedge funds and other institutional investors own 14.44% of the company’s stock.
VYNE Therapeutics Company Profile
VYNE Therapeutics Inc, a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis.
- Get a free copy of the StockNews.com research report on VYNE Therapeutics (VYNE)
- Is Clothier V.F. Corporation’s 7% Dividend Worth Trying On?
- 3 Reasons Another Shoe May Drop for Skechers
- Bulls Vs Bears: Mullen Automotive Short Interest Grows
- Palantir Falls Into The Hands Of Value Investors
- The Analysts Can’t Keep Up with Arista Networks Stock
Receive News & Ratings for VYNE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VYNE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.